Abstract Background The sirolimus-eluting stent (SES) has dramatically reduced the rate of restenosis in comparison to that with the bare-metal stent (BMS
Introduction

The Sirolimus-eluting stent (SES) has dramatically reduced the rate of restenosis in comparison to that with the bare-metal stent (BMS) (1, 2). However, a pathologic study revealed delayed healing and poorer endothelialization in patients treated with an SES rather than a BMS (3). In a previous study of coronary stenting, an early restenosis phase (to 6 months) and an intermediate-term regression phase (from 6 months to 3 years) were observed after BMS implantation (4). The long-term response to SES implantation remains unclear. To evaluate 6-month and 1-year outcomes after SES implantation, angiographic follow-up data were analyzed.
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Results
Patient and lesion characteristics
Characteristics of the patients and lesions are shown in
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Outcomes of angiographic follow-up
Six-month follow-up coronary angiography was performed for 2,628 BMS-treated lesions and 396 SES-treated lesions (follow-up rates were 78.1% and 87.9%, respectively). The restenosis rate was lower with the SES than with the BMS (Table 4). At 6 months, 615 lesions in the BMS group and 19 lesions in the SES group required repeat angioplasty (Fig. 1). Among the remaining 2,013 lesions in
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Discussion
According to a previous study, the response to BMS implantation is characterized by at least two phases, an early restenosis phase (to 6 months) and an intermediate-term regression phase (from 6 months to 3 years) (4). The intermediate-term regression phase was observed in the present study. MLD of the BMS-treated lesions that did not show restenosis upon 6-month follow-up angiography increased significantly between 6 months and 12 months. Such a regression phase was not only observed in the SES group but also stenosis of SES-treated lesions progressed. An animal study revealed that this intermediate-term regres-sion was attributable mainly to a reduction in proteoglycan content, with no change in smooth muscle cell density or the total amount of collagen (5). Therefore, this intermediate-term regression may mean the stabilization of stented segment. SES implantation may impair endothelial function in humans
Conclusion
From 6 months to 1 year after stent implantation, stenosis of BMS-treated lesions regressed, but stenosis of SEStreated lesions progressed. After 1 year, careful follow-up is needed in patients treated with an SES.
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